Prof. Christine Mauz-Körholz (Justus-Liebig-Universität Gießen, Germany) presented the results of the Checkmate 744 trial [1], which tested a new therapy in children, adolescents, and young adults 5-30 years old (CAYA) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL), particularly those who do not achieve complete metabolic response (CMR) before autologous haematopoietic cell transplantation (auto-HCT). First salvage therapy with nivolumab + brentuximab vedotin (BV) has shown a CMR rate of 67% and a 2-year progression-free survival (PFS) rate of 79% in adults with R/R cHL, but it is unknown how this translates to CAYA. CheckMate 744 is an ongoing phase 2 study for CAYA with R/R cHL (at least prior anti-cancer therapy that did not work, including autologous stem cell transplant), using a risk-stratified, response-adapted approach with nivolumab + BV followed by BV + bendamustine for patients with a suboptimal response.
Standard-risk patients (n=44, median age 16 years, with 71% <18 years old) received 4 cycles of induction with nivolumab + BV; those without CMR by blinded independent central review (BICR) received BV + bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (HDCT/auto-HCT). The primary endpoint was CMR rate (Deauville ≤3) at any time before consolidation, as determined by the BICR.
With a median follow-up of 20.9 months, 43 patients had received 4 induction cycles and 11 received intensification, 9 of whom proceeded to consolidation per protocol. CMR rate by BICR any time before consolidation was 88% (90% CI, 77-95; Table). CMR rate and ORR by BICR after induction were 59% and 82%, respectively (Table). 9 of the 11 (82%) patients who received intensification achieved CMR. Progression-free survival at 1 year was 91% (90% CI 77–96).
Table: CMR and ORR per BICR and investigator in response-evaluated patients
During induction, 70% patients had any-grade treatment-related adverse events (TRAEs); 18% were grade 3-4. The most common any-grade TRAEs were nausea and hypersensitivity (20% each). There was 1 TRAE (grade 3 anaphylaxis) leading to discontinuation. Treatment-related immune-mediated AEs were mostly grade 1–2, except for 1 patient who had 2 grade 3 infusion-related reactions.
In conclusion, this nivolumab and BV-based, risk-stratified, response-adapted salvage strategy had high CMR rates and was well tolerated with no new safety signals in CAYA with R/R cHL. Most patients did not require bendamustine intensification. Durability of disease control will require further studies.
- Mauz-Körholz C, et al. Response-adapted therapy with nivolumab + brentuximab vedotin in children, adolescents, and young adults with SD-risk R/R classical HL. EHA25 Virtual, 11-21 June 2020, Abstract S224.
Posted on
Previous Article
« Unrecognised role of iron in neutrophil differentiation Next Article
Netrin-1 regulates haematopoietic stem cells »
« Unrecognised role of iron in neutrophil differentiation Next Article
Netrin-1 regulates haematopoietic stem cells »
Table of Contents: EHA 2020
Featured articles
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
Bench-to-Bedside Science from the Presidential Symposium
Microbiome predicts B-ALL predisposition
Netrin-1 regulates haematopoietic stem cells
Unrecognised role of iron in neutrophil differentiation
Related Articles
September 9, 2020
Isatuximab triplet improves PFS in R/R MM
September 9, 2020
Two trials: acalabrutinib in CLL
September 9, 2020
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com